Stacie Pridden: My new lungs don't work any more
Stacie Pridden, 26, from Swindon, waited three years for a rare heart and double lung transplant. Here, she details her journey - and pleads for more governmental support.
Mehra M. Challenges, diligence, and a breakthrough in donation after circulatory death in heart transplantation. J Heart Lung Transplant 2017;36(12):1319-1321.
Max Olivares has a rare heart and lung condition, which requires a complex transplant operation.
This study represents the first linkage analysis between Pedimacs and Pediatric Heart Transplant Study databases to determine the effects of VAD course on post-transplant outcomes.
Acute cellular rejection(ACR) is a common complication in the first year after heart transplantation(HT). Routine surveillance for ACR is undertaken by endomyocardial biopsy(EMB). Measurement of Cardiac troponins(cTn) in serum is an established diagnostic test of cardiac myocyte injury. This systematic review aimed to determine if cTn measurement could be used to diagnose or exclude ACR.
This study examined changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients undergoing BPA for inoperable CTEPH and related them to periprocedural success.
Conclusions: Posttransplant MNs have a latency period between that seen in AML/MDS related to alkylators and that associated with topoisomerase II inhibitors. The cytogenetic profile suggests a mutagenic effect on leukemogenesis. The clinical outcome for AML/MDS is dismal, with death occurring at an early phase of treatment. PMID: 29228125 [PubMed - as supplied by publisher]
Nowadays, noninvasive imaging plays an essential role in diagnosis, prognosis and management of pulmonary arterial hypertension. The Fifth World Symposium on Pulmonary Hypertension (PH) highlighted the importance of right heart failure in pulmonary hypertension. It is defined as “a complex clinical syndrome due to suboptimal delivery of blood or elevated systemic venous pressure at rest or exercise as a consequence of elevated right ventricular afterload”, taking into account physiological demands, and both systolic and diastolic function of the ventricle-arterial coupl ing.
Heart transplantation remains the gold standard for the management of end-stage heart failure. Transplantation of sensitized patients has increased over the past 25 years.1 With more patients being bridged with durable ventricular assist devices (VADs), improved survival of the congenital heart disease population and increased re-transplantation, the pool of sensitized patients eligible for transplant is expected to rise.2 Patients with circulating HLA antibodies face increased waitlist mortality owing to longer time required to find an acceptably mismatched donor.
The ROADMAP study showed survival with improved functional status was better with left ventricular assist device (LVAD) therapy compared to optimal medical management (OMM) in ambulatory, non-inotrope dependent (INTERMACS [IM] profile 4-7) patients. To study more balanced cohorts and better define which patients may benefit from implantation of an LVAD, we re-evaluated the patients enrolled in ROADMAP stratified by INTERMACS profile (4 and 5-7).
To the Editor: